HCW Biologics Inc. cash flow to debt ratio of -196.67% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

HCW Biologics Inc.'s free cash flow has increased -7.57% from $-14.49M last year to $-13.39M, signaling increasing performance

HCW Biologics Inc.'s debt to equity ratio is 1.14, which means that the company's assets are unhealthy financed, signaling financial risk.

HCW Biologics Inc.'s debt has increased relative to shareholder equity from -2.02 last year to 1.14 today, signaling weakened financials

HCW Biologics Inc. has negative EBITDA, making leverage ratio unreliable

HCW Biologics Inc.'s interest coverage ratio is -13.21, which means that the company struggles to meet interest obligations, signaling financial risk.

HCW Biologics Inc.'s profit margin has increased (-97.89%) in the last year from -1.17K% to -24.73%, signaling increasing performance

HCW Biologics Inc.'s short-term liabilities of $21.06M exceed its short-term assets of $2.28M, signaling financial risk

HCW Biologics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

HCW Biologics Inc.'s return on equity of -102.39%, is lower than 15.00%, indicating bad performance

HCW Biologics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

HCW Biologics Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

HCW Biologics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

HCW Biologics Inc. has negative free cash flow, indicating cash burn

HCW Biologics Inc.'s yearly earnings has increased -73.49% since last year from $-30.02M to $-7.96M, signaling increasing performance

HCW Biologics Inc.'s yearly revenue has decreased 97.89% since last year from $2.57M to $54.23K, signaling decreasing performance

ROIC -38.43% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

HCW Biologics Inc.'s 3-year revenue CAGR of -79.94% is negative, indicating declining revenue over the past 3 years

HCW Biologics Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

HCW Biologics Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

HCW Biologics Inc. has insufficient data to evaluate this check.

HCW Biologics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

HCW Biologics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

HCW Biologics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

HCW Biologics Inc. has insufficient data to evaluate this check.

HCW Biologics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

HCW Biologics Inc. has a price-to-book ratio of 0.20x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

HCW Biologics Inc. has a price-to-sales ratio of 0.17x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue